Rachel Haurwitz, Caribou Biosciences CEO
April 5, 2024 04:58 AM EDTUpdated 10:33 AM
R&D
Cell/Gene Tx

‘Look be­fore you leap’: Cari­bou to start Ph1 au­toim­mune study of CAR-T ther­a­py

Lei Lei Wu

News Reporter

Just like oth­er cell ther­a­py com­pa­nies, Cari­bou Bio­sciences is en­ter­ing the au­toim­mune dis­ease field.

The Berke­ley, CA-based biotech dis­closed Thurs­day af­ter­noon …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times